Please assess the completion status of the following clinical trial:

Trial Title: Combining Curcumin With FOLFOX Chemotherapy in Patients With Inoperable Colorectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histological or cytological diagnosis of metastatic colorectal cancer~* Measurable disease by Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1) (Appendix 1)~* Adequate haematological, hepatic and renal function~* Age ≥ 18 years~* Eastern Cooperative Oncology Group (ECOG) Performance status 0 or 1~* Patients must have recovered from effects of any recent major surgery~* Willing to use contraception if applicable~* Informed consent~* Life expectancy estimated to be more than 12 weeks~Exclusion Criteria:~* Main exclusion criteria~* Contraindications to FOLFOX chemotherapy: Peripheral neuropathy NCI CTC \>1, Liver failure, uncontrolled coronary heart disease, myocardial infarction within the previous 6 months.~* Unwilling or unable to comply with the study protocol.~* Patients who are pregnant or lactating or contemplating pregnancy. Patients or their partners who become pregnant during the study will be referred to the appropriate experts.~* Undergone chemotherapy (other than adjuvant for CRC) or participating in another drug study.~* Previous cancer \<5 years (other than colorectal, basal cell carcinoma, in-situ cervical cancer).~* Major surgery within 4 weeks of starting the study~* Co-existing active infection or serious concurrent medical condition~* Significant cardiovascular disease~* Bone metastases~* Known brain or leptomeningeal metastases~* Surgery or hospital admissions for symptomatic intra-abdominal adhesions~* Active endoscopically proven peptic ulcer disease or colitis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chemotherapy only (Type: ACTIVE_COMPARATOR): Patients receiving up to 12 cycles of therapy. Standard care pathway management.
- Chemotherapy plus curcumin (Type: EXPERIMENTAL): Patients taking daily oral curcumin for up to 12 cycles of therapy. Standard care pathway management.

Based on this trial design, predict the completion outcome and termination type (if applicable).